[Application of induced pluripotent stem (iPS) cells for nerve injury in the central nervous system].
Induced pluripotent stem cells (iPSCs), with both pluripotency and replication competence similar to embryonic stem cells (ESCs), have been developed from mouse fibroblasts in 2006 by Yamanaka et al. iPSCs are unique in employing somatic cells for their production, and can avoid ethical issues existing in ESCs. It is clear that progress in technology to produce iPSCs is one of the most crucial achievements of medicine in this century. Technology with the new pluripotent cells will offer many advantages in the field of regeneration medicine supplying new tissues to the injured organ and/or development of methodology to uncover many genetic diseases. On the other hand, we have to await adequate progress in issues regarding iPSCs, including enhanced efficiency to obtain iPSCs, the technology to produce organs from the cells, avoidance of tumorigenesis and decrease in immunity in response to iPSCs.